NASDAQ:FLDM

Fluidigm Competitors

$6.11
+0.01 (+0.16 %)
(As of 06/14/2021 11:18 AM ET)
Add
Compare
Today's Range
$6.07
$6.19
50-Day Range
$4.35
$6.10
52-Week Range
$3.36
$12.45
Volume4,097 shs
Average Volume2.15 million shs
Market Capitalization$458.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59

Fluidigm (NASDAQ:FLDM) Vs. TMO, ILMN, A, MTD, WAT, and BIO

Should you be buying FLDM stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Fluidigm, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Rad Laboratories (BIO).

Thermo Fisher Scientific (NYSE:TMO) and Fluidigm (NASDAQ:FLDM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Thermo Fisher Scientific and Fluidigm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific021802.90
Fluidigm00303.00

Thermo Fisher Scientific currently has a consensus target price of $536.8947, suggesting a potential upside of 15.19%. Fluidigm has a consensus target price of $11.6667, suggesting a potential upside of 90.94%. Given Fluidigm's stronger consensus rating and higher possible upside, analysts plainly believe Fluidigm is more favorable than Thermo Fisher Scientific.

Institutional and Insider Ownership

86.0% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 79.2% of Fluidigm shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 2.9% of Fluidigm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Fluidigm's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$32.22 billion5.68$6.38 billion$19.5523.82
Fluidigm$138.14 million3.32$-53,020,000.00($0.50)-12.22

Thermo Fisher Scientific has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Thermo Fisher Scientific has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Profitability

This table compares Thermo Fisher Scientific and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific22.08%28.95%14.58%
Fluidigm-38.98%-28.73%-12.72%

Summary

Thermo Fisher Scientific beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Fluidigm (NASDAQ:FLDM) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Fluidigm and Illumina, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fluidigm00303.00
Illumina47602.12

Fluidigm currently has a consensus price target of $11.6667, suggesting a potential upside of 90.94%. Illumina has a consensus price target of $374.50, suggesting a potential downside of 16.87%. Given Fluidigm's stronger consensus rating and higher possible upside, research analysts plainly believe Fluidigm is more favorable than Illumina.

Insider & Institutional Ownership

79.2% of Fluidigm shares are held by institutional investors. Comparatively, 89.7% of Illumina shares are held by institutional investors. 2.9% of Fluidigm shares are held by company insiders. Comparatively, 0.2% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Fluidigm and Illumina's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fluidigm$138.14 million3.32$-53,020,000.00($0.50)-12.22
Illumina$3.24 billion20.31$656 million$4.50100.15

Illumina has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Fluidigm has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Illumina has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Profitability

This table compares Fluidigm and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fluidigm-38.98%-28.73%-12.72%
Illumina18.14%14.81%9.02%

Summary

Illumina beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Fluidigm (NASDAQ:FLDM) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Fluidigm and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fluidigm-38.98%-28.73%-12.72%
Agilent Technologies15.90%24.14%11.98%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Fluidigm and Agilent Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fluidigm00303.00
Agilent Technologies042002.83

Fluidigm currently has a consensus price target of $11.6667, suggesting a potential upside of 90.94%. Agilent Technologies has a consensus price target of $112.0895, suggesting a potential downside of 22.13%. Given Fluidigm's stronger consensus rating and higher possible upside, research analysts plainly believe Fluidigm is more favorable than Agilent Technologies.

Risk and Volatility

Fluidigm has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Valuation and Earnings

This table compares Fluidigm and Agilent Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fluidigm$138.14 million3.32$-53,020,000.00($0.50)-12.22
Agilent Technologies$5.34 billion8.17$719 million$3.2843.85

Agilent Technologies has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.2% of Fluidigm shares are held by institutional investors. 2.9% of Fluidigm shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Agilent Technologies beats Fluidigm on 9 of the 14 factors compared between the two stocks.

Fluidigm (NASDAQ:FLDM) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

79.2% of Fluidigm shares are owned by institutional investors. Comparatively, 92.1% of Mettler-Toledo International shares are owned by institutional investors. 2.9% of Fluidigm shares are owned by insiders. Comparatively, 3.0% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Fluidigm and Mettler-Toledo International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fluidigm$138.14 million3.32$-53,020,000.00($0.50)-12.22
Mettler-Toledo International$3.09 billion10.04$602.74 million$25.7251.77

Mettler-Toledo International has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Fluidigm and Mettler-Toledo International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fluidigm00303.00
Mettler-Toledo International23101.83

Fluidigm presently has a consensus price target of $11.6667, suggesting a potential upside of 90.94%. Mettler-Toledo International has a consensus price target of $1,048.3333, suggesting a potential downside of 21.26%. Given Fluidigm's stronger consensus rating and higher probable upside, equities analysts clearly believe Fluidigm is more favorable than Mettler-Toledo International.

Profitability

This table compares Fluidigm and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fluidigm-38.98%-28.73%-12.72%
Mettler-Toledo International20.19%195.99%23.93%

Volatility and Risk

Fluidigm has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Summary

Mettler-Toledo International beats Fluidigm on 10 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Fluidigm (NASDAQ:FLDM) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

87.4% of Waters shares are owned by institutional investors. Comparatively, 79.2% of Fluidigm shares are owned by institutional investors. 1.1% of Waters shares are owned by company insiders. Comparatively, 2.9% of Fluidigm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Waters and Fluidigm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.37 billion8.72$521.57 million$9.0536.95
Fluidigm$138.14 million3.32$-53,020,000.00($0.50)-12.22

Waters has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Waters and Fluidigm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters37101.82
Fluidigm00303.00

Waters presently has a consensus target price of $251.25, suggesting a potential downside of 24.86%. Fluidigm has a consensus target price of $11.6667, suggesting a potential upside of 90.94%. Given Fluidigm's stronger consensus rating and higher probable upside, analysts plainly believe Fluidigm is more favorable than Waters.

Profitability

This table compares Waters and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters24.56%1,107.70%22.37%
Fluidigm-38.98%-28.73%-12.72%

Risk and Volatility

Waters has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Summary

Waters beats Fluidigm on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Fluidigm (NASDAQ:FLDM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Bio-Rad Laboratories and Fluidigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories151.73%4.55%3.40%
Fluidigm-38.98%-28.73%-12.72%

Insider and Institutional Ownership

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 79.2% of Fluidigm shares are owned by institutional investors. 27.7% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 2.9% of Fluidigm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Bio-Rad Laboratories and Fluidigm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.55 billion7.03$3.81 billion$10.5257.15
Fluidigm$138.14 million3.32$-53,020,000.00($0.50)-12.22

Bio-Rad Laboratories has higher revenue and earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Bio-Rad Laboratories and Fluidigm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Fluidigm00303.00

Bio-Rad Laboratories presently has a consensus target price of $700.00, suggesting a potential upside of 16.44%. Fluidigm has a consensus target price of $11.6667, suggesting a potential upside of 90.94%. Given Fluidigm's higher probable upside, analysts plainly believe Fluidigm is more favorable than Bio-Rad Laboratories.

Summary

Bio-Rad Laboratories beats Fluidigm on 9 of the 12 factors compared between the two stocks.


Fluidigm Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.0$465.73+0.1%$182.82 billion$32.22 billion23.45
Illumina logo
ILMN
Illumina
1.2$450.67+0.6%$66.16 billion$3.24 billion105.30
Agilent Technologies logo
A
Agilent Technologies
1.7$143.82+0.2%$43.55 billion$5.34 billion48.26
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.1$1,331.46+0.4%$30.84 billion$3.09 billion48.86
Waters logo
WAT
Waters
1.3$334.38+0.7%$20.59 billion$2.37 billion33.88
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.6$601.19+0.1%$17.91 billion$2.55 billion4.42
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$354.54+0.7%$17.69 billion$2.92 billion48.04Increase in Short Interest
Bio-Techne logo
TECH
Bio-Techne
1.8$450.00+1.3%$16.95 billion$738.69 million98.25Insider Selling
Decrease in Short Interest
PerkinElmer logo
PKI
PerkinElmer
1.9$146.76+0.0%$16.46 billion$3.78 billion15.37Insider Selling
Bruker logo
BRKR
Bruker
1.6$74.33+1.1%$11.14 billion$1.99 billion55.89Decrease in Short Interest
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.7$29.55+1.1%$5.80 billion$78.89 million-79.86
Luminex logo
LMNX
Luminex
1.5$36.90+0.1%$1.74 billion$417.40 million72.35
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$7.63+0.1%$305.27 million$102.10 million-69.36
aTyr Pharma logo
LIFE
aTyr Pharma
1.7$4.79+0.8%$76.31 million$10.45 million-2.04Gap Up
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.